Table 2.

Clinical characteristics of three advanced-stage MCC patients submitted for locoregional chemotherapy during multidisciplinary treatment.

(A) Patient Id (B) Primary Site (C) Recurrence Location/Age (Years)/Stage	(A) Previous Therapy (B) Concomitant Disease (Therapy)	1st Treatment Distant Disease Status	2nd Treatment Distant Disease Status	3rd Treatment Distant Disease Status	(A) Concomitant Therapy Before Progression (B) PFS from 1st Locoregional Treatment (C) Progression Site (D) Therapy at Progression	Censor (February 2020) OS from 1st Locoregional Treatment
(A) 1 (B) Calcaneal region (C) Groin and limb /73/IIIB (pathological)	(A) WSE; SNB; CLND Chronic Neutropenia (B) Hepatitis C (Sofosbuvir/ Daclastavir)	WSE (10 nodules >1 cm diameter) IPLP	WSE (3 nodules <1 cm diameter) IPLP	WSE (1 nodule <1 cm diameter) IPLP	(A) Sofosbuvir/ Daclastavir (24 months) (B) 56 months (C) Locoregional (D) Avelumab	Dead 59 months
(A) 2 (B) Anterior abdomen (C) Pelvis and limb plus distant/58/IV (clinical)	(A) WSE and RT	WSE (7 nodules >2 cm diameter) IPLP SDi in bone metastases	WSE (5 nodules >2 cm diameter) IPLP SDi in bone metastases	WSE (4 nodules >2 cm diameter) IPLP SDi in bone metastases	(B) 7 months (C) Locoregional and distant (D) Platinum-based systemic chemotherapy until dead	Dead 12 months
(A) 3 (B) Gluteal region (C) Pelvis and limb plus distant/75/IV (clinical)	(A) WSE (B) Heart arrhythmia (Coumadin); Glaucoma (Propanolol)	WGSE/CLND (5 metastatic lymph nodes) IPLP SDi in lung, liver and brain metastases	IPLP alone SDi in lung, liver and brain metastases		(A) Coumadin/ Propanolol (B) 3 months (C) Locoregional and distant (D) Platinum-based systemic chemotherapy for 23 months	Dead 30 months

PFS, progression free survival; OS, overall survival; IPLP, isolated pelvic limb perfusion; WSE, wide surgical excisions; WGSE, wide gluteal surgical excision; SNB, sentinel lymph node biopsy; CLND, complete lymph node dissection; SDi, stable disease; RT, radiotherapy.